BNGO News and Press, Bionano Genomics Inc. From 11/28/22

Acquisition adds isotachophoresis (ITP), a proprietary technology licensed exclusively from Stanford University and developed by Purigen Biosystems for isolation and purification of nucleic acids, to the arsenal of tools for potentially simplifying ultra high molecular weight (UHMW) DNA...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Many people have trouble deciding where to invest their money. There are so many options, but it can be difficult to decide which one of them is the best. However, the current market can seem like a bonanza for the risk-tol...

SAN DIEGO, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study utilizing optical genome mapping (OGM) to detect structural variants (SVs) and balanced rearrangements relevant to prostate cancer (PCa) pathogenesis. OGM identified...

SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has appointed Donna Polizio as its global head of market access, further strengthening its leadership team. The appointment of a global head of market access reflects Bionano’s ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips During the current earnings season, a few of the companies whose stocks I own delivered great third-quarter results. These results, along with their other achievements, shows that the firms’ technologies are being wi...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It may seem a little crazy to talk about finding cheap penny stocks to buy at this time. The economy is cooling, and even blue-chip stocks are struggling to gain traction. However, there are several reasons for speculative ...

Image source: The Motley Fool. Bionano Genomics, Inc (NASDAQ: BNGO) Q3 2022 Earnings Call Nov 03, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Bionano Genomics, Inc (BNGO) Q3 2022 Earnings Call Transcript

Bionano Genomics, Inc. (BNGO) Q3 2022 Earnings Conference Call November 3, 2022 16:30 ET Company Participants Amy Conrad - Investor Relations Erik Holmlin - Chief Executive Officer Christopher Stewart - Chief Financial Officer Conference Call Participants ...

Bionano Genomics ( NASDAQ: BNGO ) saw its Q3 2022 net loss widen 53% to ~$31.8M compared to the prior-year period. However, revenue of ~$7.2M was a ~55% year-over-year increase and a beat . Consensus was $6.79M. Bionano saw a significant surge in operating expenses...

Bionano Genomics press release ( NASDAQ: BNGO ): Q3 net loss of $31.81M. Revenue of $7.22M (+54.9% Y/Y) beats by $0.43M . Grew the installed base of Saphyr systems from 196 at the end of Q2 2022 by 21 to 217 as of the end of Q3 2022, an 11% increase compared to Q2 ...